GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

Fedor, M.Sezer, A.2022-09-132022-09-1320211556-08641556-0864http://hdl.handle.net/11727/7720enginfo:eu-repo/semantics/closedAccessROS1(+)ALK(+)lorlatinibGLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC PatientsConference Object163S656S656000631349602018